These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Isolation and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. An evaluation of the biological properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine]. Ttitova TI, Grigor'ev NI, Antsiferova NG, Radkevich SA, Moroz AF. Zh Mikrobiol Epidemiol Immunobiol; 1985 Jul; (7):14-8. PubMed ID: 3931392 [Abstract] [Full Text] [Related]
3. [Production and experimental testing of the polyvalency of corpuscular vaccine for the prevention of Pseudomonas aeruginosa infections II. Experimental testing of the immunogenicity of polyvalent corpuscular Pseudomonas aeruginosa vaccine]. Moroz AF, Antsiferova NG, Radkevich SA, Mishina VS. Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):74-80. PubMed ID: 6800165 [Abstract] [Full Text] [Related]
8. Effects of a glycopolypeptide from the slime of P. aeruginosa on phagocytosis by mouse macrophages. Nadaud M. Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1983 Jul; 254(4):489-99. PubMed ID: 6426197 [Abstract] [Full Text] [Related]
12. [Derivation and experimental evaluation of polyvalent corpuscular vaccine for prevention of infections caused by Pseudomonas aeruginosa. I. Development of polyvalent corpuscular vaccine]. Moroz AF, Radkevich SA, Antsiferova NG, Brodinova NS. Zh Mikrobiol Epidemiol Immunobiol; 1981 Jul; (8):44-9. PubMed ID: 6171956 [No Abstract] [Full Text] [Related]
13. [Effectiveness of tobramycin and immunologic preparations in experimental Pseudomonas infection]. Minukhin VV, Tsyganenko AIa. Antibiot Khimioter; 1989 Apr; 34(4):282-6. PubMed ID: 2502083 [Abstract] [Full Text] [Related]
14. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers]. Bbukowska D, Serafińska D, Rudowski W, Hoffman S, Olański W, Gardzińska E, Popiel D, Jedrzejczak G, Czarnecka I. Pol Tyg Lek; 1989 Apr; 44(43-45):924-7. PubMed ID: 2518666 [Abstract] [Full Text] [Related]
15. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Zaidi TS, Priebe GP, Pier GB. Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743 [Abstract] [Full Text] [Related]
16. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection. Faezi S, Safarloo M, Amirmozafari N, Nikokar I, Siadat SD, Holder IA, Mahdavi M. APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581 [Abstract] [Full Text] [Related]
17. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model. Bakht Azad S, Nikokar I, Faezi S, Rasooly S, Mahdavi M. Microb Pathog; 2018 Oct; 123():426-432. PubMed ID: 30075242 [Abstract] [Full Text] [Related]
18. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa]. Serafińska D, Bukowska D, Sokołowska K, Nasiłowski W. Pol Tyg Lek; 1980 Jul 07; 35(27):1013-5. PubMed ID: 6775310 [No Abstract] [Full Text] [Related]